Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy

Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy

Abstract Background The COVID-19 pandemic and consequent public health response may have undermined key responses to the protracted drug poisoning crisis, including reduced access to opioid agonist therapy (OAT) among people with opioid use disorder. Our study objectives were to estimate the prevale...

Full description

Bibliographic Details
Main Authors: Soroush Moallef, Kora DeBeck, Nadia Fairbairn, Zishan Cui, Rupinder Brar, Dean Wilson, Cheyenne Johnson, M.-J. Milloy, Kanna Hayashi
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Addiction Science & Clinical Practice
Subjects:
COVID-19
Opioid agonist therapy
Medication for opioid use disorder
Overdose
Online Access:https://doi.org/10.1186/s13722-022-00354-x

Internet

https://doi.org/10.1186/s13722-022-00354-x

Similar Items